GSK Statement: Changes to distribution rights for the OmniPod® Insulin Management System in Canada
26 February 2015
Through an exclusive distribution agreement with Insulet Corporation (Insulet) signed in 2011, GSK introduced Canadians living with Type-1 diabetes to the OmniPod® System, a wirelessly controlled, tubeless, waterproof* insulin pump. GSK and Insulet propose to transfer the distribution rights for the device within Canada, the only country in which GSK had a distribution agreement, to Insulet Canada Corporation.
Our ultimate goal is to minimize disruption for patients and customers throughout the transition, which we anticipate will be fully completed by the end of June, 2015.Together with Insulet, the originator and manufacturer of the OmniPod® System, we are actively working to ensure the support channels currently in place for patients and the process to receive supply of the OmniPod® System will remain consistent once the transfer is complete.
The decision to transfer the distribution rights for the OmniPod® System is aligned with GSK’s global strategy of creating a simpler, stronger and more balanced platform for long-term growth, and a focus on further establishing GSK’s leadership in respiratory, vaccines, consumer healthcare and HIV/AIDS. Likewise, this transfer is consistent with Insulet’s interest in accelerating the growth of its global business.
*waterproof to 7.6 meters for up to 60 minutes (IPX8 rating)
|Corporate Communications||+1 905-819-3363||(Mississauga)|